ARTICLE | Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

October 15, 2018 2:41 PM UTC

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy strategies.

The biotech will receive up to $125 million in an upfront payment and near-term milestones. SQZ is also eligible for $250 million in clinical, regulatory and sales milestones per resulting product, plus royalties...

BCIQ Company Profiles


SQZ Biotechnologies Co.